Sanofi: agreement for acquisition of Bioverativ
(CercleFinance.com) - Sanofi and Bioverativ have announced a definitive agreement under which Sanofi will purchase all of Bioverativ's outstanding shares at 105 dollars per share in cash, meaning a transaction value of approximately 11.
6 billion dollars.
With Bioverativ, a leader in the growing market of haemophilia, Sanofi will strengthen its presence in specialty drugs, along with its leadership in rare diseases, in line with its roadmap for 2020, said Olivier Brandicourt, CEO at Sanofi.
The French health group will launch a takeover bid which should begin in February 2018, the closure of which is subject to certain conditions, including the provision of at least the majority of Bioverativ's outstanding shares.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
6 billion dollars.
With Bioverativ, a leader in the growing market of haemophilia, Sanofi will strengthen its presence in specialty drugs, along with its leadership in rare diseases, in line with its roadmap for 2020, said Olivier Brandicourt, CEO at Sanofi.
The French health group will launch a takeover bid which should begin in February 2018, the closure of which is subject to certain conditions, including the provision of at least the majority of Bioverativ's outstanding shares.
Copyright (c) 2018 CercleFinance.com. All rights reserved.